Eli Lilly Reports Phase 3 subgroup analysis Data for Risdiplam in Merkel cell carcinoma

Eli Lilly today announced Phase 3 subgroup analysis results for Risdiplam in patients with Merkel cell carcinoma. The study demonstrated that Risdiplam reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Merkel cell carcinoma and support the continued development of Risdiplam in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Risdiplam was consistent with previous observations, with no new safety signals identified.